Our specialist multi-disciplinary LIFE SCIENCES team advises businesses at all stages of the medicines supply chain

Life Sciences

Our multi-disciplinary life sciences team advises a wide range of clients in the life sciences sector including some of the world’s largest pharmaceutical companies, biotech companies, healthcare providers and medical devices manufacturers. 

We advise life sciences companies at all stages of the medicines supply chain on the full range of legal issues affecting them including competition, regulatory and compliance, intellectual property including patents and trade marks, product life cycle, clinical trial agreements, collaboration, licensing and other commercial transactions.

We also have extensive experience of advising on acquisitions in the life sciences area and in advising banks and financial institutions with an interest in this space.

 

 

  • Intellectual Property

    Intellectual property rights are of vital importance to companies in the life sciences sector and are often the most valuable assets of the business. We can help companies in the life sciences and healthcare space to effectively and efficiently protect and exploit their intellectual property rights.

    We have extensive experience of handling litigation at all levels of the UK courts, as well as managing multi-jurisdiction disputes and working with leading IP practitioners in the overseas territories in which our clients are active. However, an equally important aspect of our work is advising on the effective protection, use and licensing of IP rights to maximise our clients’ commercial advantage and prevent disputes arising. Our team advises on the full range of contentious and non-contentious intellectual property including patent litigation and licensing, and trade secrets litigation.

  • Commercial Agreements

    Our Commercial team has extensive experience and in-house expertise of the legal issues that affect life sciences and healthcare companies on a daily basis.

    Our experience extends to generics, animal health, eye care, innovators, manufacturers, vaccines, medical devices as well as biotech and delivery systems. In particular, we work closely with in-house life science and pharmaceutical teams and regularly assist with the drafting, negotiation and termination of commercial agreements. These include NDAs, clinical trials, joint working agreements and collaboration arrangements, sales or purchase terms, rebates, sales of marketing authorisations. We also advise on manufacturing and supply contracts, warehousing and logistics, standard template agreements, appointment of field sales teams, outsourcing and procurement and licensing and marketing contracts.

  • Competition and EU law

    Ensuring compliance with competition law should be a key priority of any life sciences and healthcare business.  Because of the importance of the sector to the global economy, and the dynamic nature of life sciences markets, the sector is, and will continue to be, a high priority for enforcement.  Competition law can also provide an opportunity for businesses to ensure that competitors play fair, and can result in substantial damages being awarded for infringements.

    Our competition team is hugely experienced in the life sciences sector.  We have many years’ experience of working with regulators and companies in this area.  Experience includes advisory work, implementing compliance training, acting in relation to government investigations and dawn raids and carrying out litigation including judicial review of government policy.

  • Regulatory

    Pharmaceutical and biotechnology businesses are subject to a huge range of regulations.  In addition to general regulations (e.g. anti-bribery and corruption, competition law and data privacy), life sciences businesses are required to comply with a range of sector specific regulations and voluntary schemes.

    We have experience of advising on both general and sector specific regulations impacting life sciences businesses.  We have provided compliance training and have assisted businesses on issues as they arise.  These include government investigations, including dawn raids, issues arising in the context of commercial and corporate transactions and day to day issues facing businesses.

  • Dispute Resolution

    We have considerable experience of handling disputes arising for clients in the life sciences sector over many years. We often work closely with the client’s in-house team and have developed a detailed understanding of the sector and what is important for their businesses.

    Our work involves advice on issues as they emerge, mediation, litigation and arbitration.  Where urgent situations arise we have considerable experience of seeking injunctive relief to prevent damage or loss.

    In addition to disputes arising under licensing, supply and development agreements, we also deal with other issues such as product recall and claims arising. We also act for life sciences clients in relation to construction and engineering disputes.  

    Examples of our experience include:

    - Successfully representing a multinational pharmaceutical company relating to a multi-million pound cross-border fraud to obtain freezing and seizure orders

    - Acting for pharmaceutical clients in relation to dawn raids by the SFO on their UK offices

    - Acted for an international life sciences company in an ICC arbitration against a foreign life sciences company 

  • Corporate and Banking

    We have experience of advising both buyers and sellers of companies and businesses in the pharmaceutical, life sciences and healthcare sectors. This includes management teams on leveraged transactions.

    We have advised on equity fundraisings including private equity and development capital transactions and debt transactions including traditional senior bank debt but also warrants and other forms of finance.

  • Data Protection

    Data protection issues are now high profile and often come under the spotlight.  We act for organisations looking to resist Freedom of Information requests or dealing with Data Protection or data licensing issues. The arrival of the General Data Protection Regulations means that we are helping many organisations to prepare for its impact. Our team is well versed in data protection issues and has in-house experience for a worldwide major pharmaceutical company on data protection issues.

    Our advice covers data licensing, dealing with sensitive personal data, data breaches, appointment of data processors in outsourced IT and services, transfers of personal data outside the EEA, making and resisting data subject access requests and freedom of information requests. We draft privacy and cookies notices, advise on notifications to the Information Commissioner’s office and assist in the preparation of policies and standard operating procedures including for surveillance and interception of emails and privacy impact assessments.

    We work closely with our international colleagues on trans-border transactions and provide advice on implementation of the General Data Protection Regulations.

Our experience

  • Advising the UK stakeholders responsible for UK’s overall implementation of the Falsified Medicines Directive
  • Advising an international pharmaceutical company on complex patent, regulatory and data protection issues
  • Assisting a global pharmaceutical company on successful Judicial Review of Home Office policy

A taxing time for Toys 'R' Us

Before Christmas we reported on the struggles faced by the UK arm of Toys ‘R’ Us, and in particular what seemed like a last minute saving grace for the retailer in the form of a Company Voluntary Arrangement (CVA) . Despite the CVA proposals...

Read more

The name is Bond, QC Bond (or non-QC Bond)

Everyone loves a good acronym. GIF** is one that internet bloggers and the social media savvy will know all about!  But how many of our readers have heard of a QC bond or a “QCB” and know what it means?  A few entrepreneur...

Read more

Fintech companies prepare for Brexit

S&B's Jackie Penlington comments in an article on the fintech industry's Brexit preparations in Computer Weekly. Please see the full article available online here ....

Read more

High Court decision highlights contractual termination pitfalls

A recent decision of the High Court highlighted the importance of parties thinking carefully about whether they are entitled to bring a contract to an end and properly informing the other contracting party of the grounds for termination.    ...

Read more

EMA relocation: Amsterdam will not be ready and Milan's appeal

In the latest on the relocation of the European Medicines Agency (EMA), it has been reported that Italy intends to challenge the decision to move the EMA from London to Amsterdam after Brexit.  In November last year, Milan narrowly lost out to...

Read more

How will autonomous vehicles impact the retail and logistics real-estate sector?

S&B's Ian Craig and Mary Liu provide their expertise on the impact autonomous vehicles will have on the retail and logistics real-estate sector in their new article in RICS Property Journal. Please see the full article online ....

Read more

The dangers of staff becoming "accidentally illegal"

Jackie Penlington covers the dangers of staff becoming “accidentally illegal” in this recent article in Real Business. Please find the full article available online....

Read more

Protection for property owners against fraud

Some property is particularly vulnerable to fraud, for example high value, unoccupied, mortgage-free, and (in some cases) tenanted properties.  While high profile fraud cases have usually involved residential property, commercial property owners should...

Read more

New worker rights being proposed by the Government

S&B's Lloyd Davey shares details on new worker rights being proposed by the Government in Essential Retail. Please see the full article available here ....

Read more

How to help ensure a neighbour's flat extentsion goes smoothly

Stephen Rockhill from our real estate team provides advice to make sure a neighbour's flat extension project goes smoothly in The Sunday Times. Please see the full Q&A article on The Times website. (registration required)...

Read more

CAP issues guidance on travel marketing

The Committee of Advertising Practice (CAP) Executive has published guidance on travel marketing availability and pricing in response to a number of complaints from consumers. The rules around prompts and inducements to customers in advertising have...

Read more

Government response to Taylor study provides no new employment rights for flexible workers

S&B's Kerry Garcia provides expertise on this long-awaited government response to a study on modern work practices in People Management. Please see the full article here ....

Read more

Brexit uncertainty and limited availability of skilled staff

Jackie Penlington comments on how Brexit may be fuelling increased visa demand in this recent article in Computer Weekly. Please see the full article here ....

Read more

High Court confirms limited application of frustration of contract

The High Court has recently emphasised the limited availability of the doctrine of ‘frustration of contract’ in a case concerning a theatrical production amid civil unrest in Greece.   Background It is well established that the parties to...

Read more

'Compensatory rest' periods must be given in 20-minute continuous blocks of time and cannot be offered piecemeal

In a recent decision that will concern all employers, the Employment Appeal Tribunal (‘EAT’) clarified the meaning of ‘equivalent period of compensatory rest’ under Regulation 24 of the Working Time Regulations 1998 in Crawford v Network Rail Infrastructure Ltd. and held that an employer must provide workers with a 20 minute period of continuous rest for every 6 hours worked.

Read more

Buyers beware - get your warranty claim notice right

Two recent decisions have highlighted the need for buyers to take extreme care to ensure that they properly notify intended claims under a share purchase agreement (“SPA”).  When selling a company, sellers will usually be required to make...

Read more

Starbucks wins EU General Court decision against Coffee Rocks trade mark

We are never far away from a Starbucks, and few people could fail to recognise the coffee shop’s iconic mermaid trade mark. Eager to protect its famous logo, Starbucks has now won a long fought for General Court ruling declaring that the logo of a...

Read more

Is Louboutin's red-sole trademark in jeopardy?

Elaine O’Hare from S&B helps explain the 6 February preliminary opinion on the Louboutin case in a number of publications. Please see the following: brandchannel Drapers (requires subscription) ExecReview The Guardian The Times...

Read more

Court validates "bogus" appointment of administrators

In Endersby and Coote v Astrosoccer 4 U Ltd (7 December 2017) , the High Court considered whether to make a retrospective administration order over a company that had been subject to an outstanding winding-up petition at the time when administrators were...

Read more

Legal agreements for early-stage and growing businesses

S&B's Nick Atkins and Katie Philipson offer their expertise on legal agreements for early-stage and growing businesses in this recent article in Small Business. Please find the full article here ....

Read more

Update on the duty to report on payment practices legislation

Oliver Kidd comments on the duty to report on payment practices legislation in this article appearing on the GoCardless industry blog. Please see the full article here ....

Read more

MHRA updates pharmaceutical companies on preparations for exiting the EU

On 8 December 2017 the UK Government and the EU negotiators published a Joint Report on the progress made during the first phase of Brexit negotiations. A week later, on 15 December 2017, the European Council formally agreed that enough progress had been...

Read more

A Pharma company's cry: "NICE has got it wrong! What can I do?"

Background to NICE and its role The National Institute for Health and Clinical Excellence (or NICE) was set up in 1999 to reduce the variation in the availability and quality of NHS treatments and care. In 2005 it merged with the Health Development Agency...

Read more

How IP law applies to AI copyright claims

Tom Lingard provides his expertise in this recent article from Techworld. Please see the full article here ....

Read more

What should be included in a founders' agreement?

Learn more from Nick Atkins and Katie Philipson in this new article published by Real Business. Please see the full article here ....

Read more

What are my options when my franchisor fails?

Nicola Broadhurst and Angelica Lovell provide options for what to do when your franchisor fails. The article is available in the latest print issue of What Franchise Magazine  and is also available as a PDF download here . ...

Read more

Non-UK residents with UK residential property may need to file tax returns twice

Please see Matthew Peto's recent article published in Spear's Magazine. The complete article is available here ....

Read more

Employer vicariously liable for employee's deliberate data breach

In a decision that will concern all employers, the High Court has held that Morrisons supermarket was liable for the deliberate data breach by one of its employees, even though he intended to cause harm to his employer. What happened? The employee in...

Read more

EU announces UK will be a 'third country' in data protection after Brexit

The European Commission in Brussels published a notice to stakeholders on 9 January 2018, stating that the United Kingdom will be recognised as a “third country” in the field of data protection after its withdrawal from the EU, subject to any...

Read more

Reviving Fashion Brands

S&B's Elaine O'Hare covers important points for reviving fashion brands in this recent article in FashionCapital. Please find the full article here ....

Read more
  • Page 1 of 10

Search our site